Contraception
Conditions
Keywords
copper intra-uterine device, Hysteroscope
Brief summary
Insertion under vision such as hysteroscopy allows the ability to visualize the uterus prior to insertion, to assess uterine compatibility and the assurance of proper device placement. ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe. This multicentre, open-label study will take place at the Women's Clinic of Ghent University Hospital in Belgium (International Coordinating Centre) and at the University Hospital AOU Federico II of Naples in Italy. Primary aim: To evaluate the safety of the ReLARC® inserter during the insertion procedure of GyneFix® intrauterine copper bearing contraceptive devices by means of successful placement with adequate position during follow-up evaluations. Providing no complications develop, participants will remain in the study for 3 years. 120 women will be enrolled.
Interventions
DEVICEReLARC
ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe.
Sponsors
Federico II University
University Hospital, Ghent
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 48 Years
Healthy volunteers
Yes
Inclusion criteria
* Generally healthy women, 18 - 48 years of age and not having a contraindication for hysteroscopy * Be willing to come back for the follow-ups * Be willing to refrain from having intercourse the first two weeks and using tampons and menstrual cups in the first 2 months, following insertion * Sign a written informed consent * Fundus thickness should be 11mm or more
Exclusion criteria
* T and Y shaped uterus * U1, dysmorphic uterus (abnormal myometrium may result in bad device fixation) * Complete septate U2b uterus * Bicorporal U3-U6 uterus * Injectables contraceptive use in the last 6 months * The presence of infection of the uterus, clinical cervicitis or vaginitis (infection should be ruled out) * Intrauterine fibroids (intra-mural, intracavitary or submucosal) * Cancer or other disease of the uterus * Malignancy, or treatment for malignancy. Melanoma or any gynaecological cancer at any time excludes the subject * Blood clotting disorders * Intrauterine polyps * Subjects receiving corticosteroid therapy or immunosuppressive drugs * Morbus Wilson * AIDS * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Positioning of the ReLARC IUD | 3 years | To evaluate the position of the ReLARC® IUD to confirm the succesful placement of the IUD with the ReLARC inserter during every follow-up visit. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Removal rate | 7 years | The number of early removal of the IUD will be registered during the trial |
| Pain at removal | 7 years | pain (VAS): 1. no pain, 2. mild pain, 3. nasty pain, 4. severe pain, 5. unbearable pain |
| Ease of removal | 7 years | The ease of removal (Likert scale): 1. very easy, 2. easy, 3. neither easy nor difficult, 4. difficult, 5. very difficult |
| Ease of insertion | During Insertion visit | 1\. The ease of the insertion (hysteroscope and ReLARC® device) by the following scale: 1. Insertion went smoothly. 2. I had little trouble while inserting the device but experienced this as a not important delay in my surgical act. 3. Insertion was rather difficult. 4. Insertion was time consuming, difficult, and dangerous. 5. Insertion was not possible due to technical issues or medical reasons. |
| Expulsion rate | 7 years | The number of expulsions of the IUD will be registered during the trial |
| Pain score | During Insertion visit | the participant's pain by a Visual Analogue Scale-VAS (1. no pain, 2. mild pain, 3. nasty pain, 4. severe pain, 5. unbearable pain) will be described. |
| patient satisfactory | 3 years after insertion | The patient satisfactory score will be determined at every follow-up visit (4-8 weeks after insertion; 1 year after insertion, 2 years after insertion and 3 years after insertion) |
| Uterine cavity transverse diameter | During insertion visit | the uterine cavity transverse diameter (UCTD) (before ReLARC® device insertion) will be described. |
| Learning curve of ReLARC insertion | During Insertion visit | 2\. The learning curve of ReLARC® insertion, that starts after introducing the scope in the cervix and ends when the thread is cut and looped. This will be reported in minutes. |
Countries
Belgium
Contacts
Primary ContactSteven Weyers, MD
Backup ContactEline Meireson, Msc
Outcome results
None listed